Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety profile comparable to 1500mg QW dose, further derisking pivotal FORTIFI-HN01 study ...

In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.

P liant Therapeutics has reported interim results from its ongoing Phase I dose escalation trial of PLN-101095, along with ...

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed ...

Perioperative enfortumab vedotin and pembrolizumab added to surgery may represent a new standard of care in this population with a high unmet medical need,” said Christof Vulsteke, MD, PhD.

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW ...

SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ -- Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading ...

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and ...

Rondo Therapeutics begins patient dosing in phase 1/1b trial of RNDO-564 in adults with r/r locally advanced or metastatic urothelial carcinoma: Hayward, California Saturday, Dece ...

Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development of PLN-101095 ...

Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose Data inform and advance progress toward dose ...

“Olomorasib, in combination with pembrolizumab, has demonstrated significant efficacy and a manageable safety profile in patients with KRAS G12C-mutant advanced/metastatic NSCLC, including patients ...